Literature DB >> 10652423

A region of common deletion in 22q13.3 in human glioma associated with astrocytoma progression.

N T Oskam1, E H Bijleveld, T J Hulsebos.   

Abstract

Loss of heterozygosity for chromosome 22 (LOH 22) occurs in gliomas of all malignancy grades. Neurofibromatosis type 2 (NF2) patients are at increased risk of developing a glioma. However, the NF2 gene in 22q12.2 is not involved in glioma tumorigenesis. To detect additional regions on chromosome 22 that may harbor tumor suppressor genes important in glioma tumorigenesis, we determined LOH 22 profiles for 159 gliomas using 32 markers. LOH 22 was found in 46 tumors (29%). Thirteen tumors displayed partial LOH 22, from which we deduced a region of common deletion between markers D22S928 and D22S1169 in 22q13.3. LOH of at least this region was detected in 13% of the astrocytomas (As), in 20% of the anaplastic astrocytomas (AAs) and in 35% of the glioblastomas multiforme (GBMs). The significant increased frequency of LOH 22q13.3 in the highest malignancy grade (GBM vs. A and AA, p = 0.02) indicates that loss of this region is associated with astrocytoma progression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10652423

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  10 in total

1.  Loss of 22q chromosome is related to glioma progression and loss of 10q.

Authors:  Florence Laigle-Donadey; Emmanuelle Crinière; Alexandra Benouaich; Emmanuelle Lesueur; Karima Mokhtari; Khe Hoang-Xuan; Marc Sanson
Journal:  J Neurooncol       Date:  2006-02       Impact factor: 4.130

Review 2.  Molecular pathogenesis of astrocytic tumours.

Authors:  Koichi Ichimura; Hiroko Ohgaki; Paul Kleihues; V Peter Collins
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

3.  Microarray analysis of pediatric ependymoma identifies a cluster of 112 candidate genes including four transcripts at 22q12.1-q13.3.

Authors:  Blanca Suarez-Merino; Mike Hubank; Tamas Revesz; William Harkness; Richard Hayward; Dominic Thompson; John L Darling; David G T Thomas; Tracy J Warr
Journal:  Neuro Oncol       Date:  2005-01       Impact factor: 12.300

4.  Tumor prognostic factors and the challenge of developing predictive factors.

Authors:  Emma B Holliday; Erik P Sulman
Journal:  Curr Oncol Rep       Date:  2013-02       Impact factor: 5.075

5.  Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications.

Authors:  Rodney N Wiltshire; James E Herndon; Annie Lloyd; Henry S Friedman; Darell D Bigner; Sandra H Bigner; Roger E McLendon
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

6.  Molecular-genetic characterisation of gliomas that recur as same grade or higher grade tumours.

Authors:  T J M Hulsebos; D Troost; S Leenstra
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-05       Impact factor: 10.154

7.  Chronophin is a glial tumor modifier involved in the regulation of glioblastoma growth and invasiveness.

Authors:  M Schulze; O Fedorchenko; T G Zink; C B Knobbe-Thomsen; S Kraus; S Schwinn; A Beilhack; G Reifenberger; C M Monoranu; A-L Sirén; E Jeanclos; A Gohla
Journal:  Oncogene       Date:  2015-11-09       Impact factor: 9.867

Review 8.  What is hidden in the pannexin treasure trove: the sneak peek and the guesswork.

Authors:  Oxana Litvin; Anya Tiunova; Yvette Connell-Alberts; Yuri Panchin; Ancha Baranova
Journal:  J Cell Mol Med       Date:  2006 Jul-Sep       Impact factor: 5.310

9.  Pannexin2 oligomers localize in the membranes of endosomal vesicles in mammalian cells while Pannexin1 channels traffic to the plasma membrane.

Authors:  Daniela Boassa; Phuong Nguyen; Junru Hu; Mark H Ellisman; Gina E Sosinsky
Journal:  Front Cell Neurosci       Date:  2015-02-02       Impact factor: 5.505

10.  The Influence of Gene Aberrations on Survival in Resected IDH Wildtype Glioblastoma Patients: A Single-Institution Study.

Authors:  Ondrej Kalita; Zuzana Sporikova; Marian Hajduch; Magdalena Megova Houdova; Rastislav Slavkovsky; Lumir Hrabalek; Matej Halaj; Yvona Klementova; Martin Dolezel; Jiri Drabek; Lucie Tuckova; Jiri Ehrmann; Jana Vrbkova; Radek Trojanec; Miroslav Vaverka
Journal:  Curr Oncol       Date:  2021-03-21       Impact factor: 3.677

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.